Medipharm Labs Corp T.LABS

Dronabinol, Nabilone, Nabiximols, Epidolex

[mdjbrown]

What's the next FDA approved CBD drug, and is Medipharm's name right in the middle of it?


https://www.ncbi.nlm.nih.gov/books/NBK425762/


CANNABINOID-BASED MEDICATIONS

Food and Drug Administration (FDA) has licensed three drugs based on cannabinoids (see Table 2-2). Dronabinol, the generic name for synthetic Δ9-THC, is marketed under the trade name of Marinol® and is clinically indicated to counteract the nausea and vomiting associated with chemotherapy and to stimulate appetite in AIDS patients affected by wasting syndrome. A synthetic analog of Δ9-THC, nabilone (Cesamet®), is prescribed for similar indications. Both dronabinol and nabilone are given orally and have a slow onset of action. In July 2016 the FDA approved Syndros®, a liquid formulation of dronabinol, for the treatment of patients experiencing chemotherapy-induced nausea and vomiting who have not responded to conventional antiemetic therapies. The agent is also indicated for treating anorexia associated with weight loss in patients with AIDS. Two additional cannabinoid-based medications have been examined by the FDA.

Nabiximols (Sativex®) is an ethanol cannabis extract composed of Δ9-THC and CBD in a one-to-one ratio. Nabiximols is administered as an oromucosal spray and is indicated in the symptomatic relief of multiple sclerosis and as an adjunctive analgesic treatment in cancer patients (Pertwee, 2012). As of September 2016, nabiximols has been launched in 15 countries, including Canada, Germany, Italy, Spain, the United Kingdom, and has been approved in a further 12, but not in the United States.5 

In response to the urgent need expressed by parents of children with intractable epilepsy, in 2013 the FDA allowed investigational new drug studies of Epidiolex®, a concentrated CBD oil (>98 percent CBD), also developed by GW Pharmaceuticals, as an anti-seizure medication for Dravet and Lennox-Gastaut syndromes.